FGFR1 and urothelial carcinoma: Pal et al. [32] evaluated the efficacy of BGJ398, an FGFR1–3 inhibitor, in advanced urothelial carcinoma with FGFR3 alterations and reported an ORR of 25.4% and a disease control rate of 64.2%.